Medherant said today that it successfully finished two Phase I studies with its ibuprofen transdermal drug-delivery patch.
According to the UK-based company, the Tepi patch was well tolerated by the participants of a skin irritation study.
Get the full story at our sister site, Drug Delivery Business News.
The post Medherant touts results for ibuprofen transdermal patch appeared first on MassDevice.